Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GRK2 | P25098 | 1/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.31 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415901 | 0.98 | APAF1 (0.31) | APAF1POLBGRK2DNMT1PTPN7 | |
| SCHEMBL5415894 | 0.98 | APAF1 (0.31) | APAF1POLBGRK2DNMT1PTPN7 | |
| SCHEMBL19423969 | 0.82 | DPP4 (0.34) | APAF1POLBGRK2DNMT1PTPN7 | |
| SCHEMBL3264990 | 0.82 | POLB (0.44) | APAF1POLBGRK2DNMT1PTPN7 | |
| SCHEMBL3264987 | 0.82 | POLB (0.44) | APAF1POLBGRK2DNMT1PTPN7 | |
| SCHEMBL9287069 | 0.79 | SPHK1 (0.31) | — | |
| SCHEMBL12189940 | 0.78 | ALDH1A1 (0.33) | APAF1POLBGRK2DNMT1PTPN7 | |
| SCHEMBL19620188 | 0.77 | POLB (0.31) | APAF1POLBGRK2DNMT1PTPN7 | |
| SCHEMBL23559897 | 0.75 | CA1 (0.33) | APAF1POLBGRK2DNMT1PTPN7 | |
| SCHEMBL19222188 | 0.75 | POLB (0.31) | APAF1POLBGRK2DNMT1PTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100178260-A1 | COMPOSITION COMPRISING A RETINOID, AN ADENOSINE-BASED NONPHOSPHATED COMPOUND, AND A SEMICRYSTALLINE POLYMER | L'OREAL (FR) | 2010-07-15 | — | — | US | disclosed |
| WO-1995032356-A1 | ADDITIVES AND METHOD FOR CONTROLLING CLATHRATE HYDRATES IN FLUID SYSTEMS | COLORADO SCHOOL OF MINES (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178260-A1 | COMPOSITION COMPRISING A RETINOID, AN ADENOSINE-BASED NONPHOSPHATED COMPOUND, AND A SEMICRYSTALLINE POLYMER | RARA, RBP4, RBP1 | APAF1 1708/4885POLB 174/4885GRK2 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.